Literature DB >> 29710717

Behavioral and Neuropsychiatric Disorders in Alzheimer's Disease.

Nicole Cortés1,2, Víctor Andrade1,2, Ricardo B Maccioni1,2,3.   

Abstract

Alzheimer's disease (AD) is the most frequent type of dementia in the elderly, severely affecting functional and executive skills of subjects suffering from this disease. Moreover, the distress of caregivers as well as the social implications constitute a critical issue for families. Furthermore, cognitive impairment, along with behavioral disorders and neuropsychiatric symptoms are characteristics of AD. Although these are present with variations in prevalence, intensity, and progression, an important core of them is visible before cognitive impairment, especially depression and apathy, which affect at least 50% of patients. The most updated literature shows that depression and/or behavioral and neuropsychiatric symptoms (BNS) are part of the initial phase of the disease rather than just a risk factor. Thus, mood disorders are associated with anomalies in specific brain regions that disturb the normal balance of neurotransmission. This in turn is linked with an inflammatory pathway that leads to microglial activation and aggregated neurofibrillary tangle formation, finally triggering neuronal loss, according to our neuroimmunomodulation theory. Altogether, inflammation and tau aggregation are observed in preclinical stages, preceding the BNS of patients, which in turn are exhibited earlier than cognitive and functional impairment detected in AD. This review is focused on the latest insights of cellular and molecular processes associated with BNS in asymptomatic early-onset stages of AD. An important medical research focus is to improve quality of life of patients, through prevention and treatments of AD, and the study of behavioral disorders and early event in AD pathogenesis has a major impact.

Entities:  

Keywords:  Alzheimer’s disease; apathy; asymptomatic stages; behavioral disorders; neuroimmunomodulation; neuroinflammation; neuropsychiatric symptoms

Mesh:

Year:  2018        PMID: 29710717     DOI: 10.3233/JAD-180005

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  12 in total

1.  The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease.

Authors:  Leah H Rubin; Erin E Sundermann; David J Moore
Journal:  J Neurovirol       Date:  2019-01-22       Impact factor: 2.643

Review 2.  Molecular mechanisms of developmental pathways in neurological disorders: a pharmacological and therapeutic review.

Authors:  Niraj Kumar Jha; Wei-Chih Chen; Sanjay Kumar; Rajni Dubey; Lung-Wen Tsai; Rohan Kar; Saurabh Kumar Jha; Piyush Kumar Gupta; Ankur Sharma; Rohit Gundamaraju; Kumud Pant; Shalini Mani; Sandeep Kumar Singh; Ricardo B Maccioni; Tirtharaj Datta; Sachin Kumar Singh; Gaurav Gupta; Parteek Prasher; Kamal Dua; Abhijit Dey; Charu Sharma; Yasir Hayat Mughal; Janne Ruokolainen; Kavindra Kumar Kesari; Shreesh Ojha
Journal:  Open Biol       Date:  2022-03-16       Impact factor: 6.411

3.  Data-driven health deficit assessment improves a frailty index's prediction of current cognitive status and future conversion to dementia: results from ADNI.

Authors:  Andreas Engvig; Luigi A Maglanoc; Nhat Trung Doan; Lars T Westlye
Journal:  Geroscience       Date:  2022-10-19       Impact factor: 7.581

4.  Cognitively stimulating activities and risk of probable dementia or cognitive impairment in the English Longitudinal Study of Ageing.

Authors:  Benjamin David Williams; Neil Pendleton; Tarani Chandola
Journal:  SSM Popul Health       Date:  2020-08-26

Review 5.  Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis.

Authors:  Giulia Menculini; Elena Chipi; Federico Paolini Paoletti; Lorenzo Gaetani; Pasquale Nigro; Simone Simoni; Andrea Mancini; Nicola Tambasco; Massimiliano Di Filippo; Alfonso Tortorella; Lucilla Parnetti
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

6.  Pontine Arteriolosclerosis and Locus Coeruleus Oxidative Stress Differentiate Resilience from Mild Cognitive Impairment in a Clinical Pathologic Cohort.

Authors:  Sarah C Kelly; Peter T Nelson; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2021-03-22       Impact factor: 3.148

7.  Soluble Fibrinogen Triggers Non-cell Autonomous ER Stress-Mediated Microglial-Induced Neurotoxicity.

Authors:  Thomas M Piers; Emma East; Claudio Villegas-Llerena; Ioanna G Sevastou; Mar Matarin; John Hardy; Jennifer M Pocock
Journal:  Front Cell Neurosci       Date:  2018-11-19       Impact factor: 5.505

8.  Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimer's Disease.

Authors:  Sarah Beggiato; Maria Cristina Tomasini; Tommaso Cassano; Luca Ferraro
Journal:  J Clin Med       Date:  2020-02-05       Impact factor: 4.241

9.  Bufo viridis secretions improve anxiety and depression-like behavior following intracerebroventricular injection of amyloid β.

Authors:  Shima Shirzad; Ali Neamati; Farzaneh Vafaee; Hamed Ghazavi
Journal:  Res Pharm Sci       Date:  2020-11-27

Review 10.  Promising Intervention Approaches to Potentially Resolve Neuroinflammation And Steroid Hormones Alterations in Alzheimer's Disease and Its Neuropsychiatric Symptoms.

Authors:  Catia Scassellati; Antonio Carlo Galoforo; Ciro Esposito; Miriam Ciani; Giovanni Ricevuti; Cristian Bonvicini
Journal:  Aging Dis       Date:  2021-08-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.